{"id":"W4396659099","doi":"10.1093/jnci/djae098","title":"Ataxia telangiectasia and Rad3-related (ATR) inhibitor camonsertib dose optimization in patients with biomarker-selected advanced solid tumors (TRESR study)","year":2024,"lang":"en","type":"article","venue":"JNCI Journal of the National Cancer Institute","topic":"DNA Repair Mechanisms","field":"Biochemistry, Genetics and Molecular Biology","cited_by":13,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"Takeda Oncology; EMD Serono; Genentech; PharmaMar; Astellas Pharma; Eisai; Springworks Therapeutics; G1 Therapeutics; Mereo BioPharma; MacroGenics; Actuate Therapeutics; Loxo Oncology; Astex Pharmaceuticals; Ribon Therapeutics; Pfizer; Incyte; BeiGene; Clovis Oncology; Daiichi Sankyo Europe; National Cancer Institute; Servier; Foghorn Therapeutics; Calithera Biosciences; AstraZeneca; Novocure; Jazz Pharmaceuticals; Puma Biotechnology; Regeneron Pharmaceuticals; Merck KGaA; Sanofi; Exelixis; GlaxoSmithKline; Plexxikon; Seagen; Relay Therapeutics; Amgen; Carrick Therapeutics; Ignyta; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Ataxia-telangiectasia; Biomarker; Medicine; Cancer research; Solid tumor; Internal medicine; Cancer; Chemistry; DNA damage; Biochemistry; DNA","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001129924,0.0004320693,0.0009086347,0.0001918719,0.0001293871,0.0003551067,0.0003373295,0.0002456717,0.001479613],"category_scores_gemma":[0.0005216455,0.0001318951,0.000647464,0.0002492461,0.0002063377,0.0002377853,0.00016934,0.000741141,0.0002691187],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004918374,"about_ca_system_score_gemma":0.0006710169,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003471023,"about_ca_topic_score_gemma":0.001060192,"domain_scores_codex":[0.999698,0.0001473877,0.00002073372,0.00005197525,0.00004377789,0.00003820256],"domain_scores_gemma":[0.9997349,0.00005770943,0.00008778691,0.00002682671,0.00002433098,0.0000683631],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.4746976,0.01611009,0.07956486,0.001060897,0.002418118,0.0004892494,0.0002818957,0.01075409,0.1625165,0.0005815716,0.005663814,0.2458613],"study_design_scores_gemma":[0.2029461,0.5022753,0.2281126,0.0001113293,0.002978467,0.001714237,0.0001325066,0.0096336,0.03673701,0.0005935315,0.01469559,0.00006972828],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9978135,0.0006922377,0.0001826625,0.00004767163,0.00000611486,0.0002170632,0.0002938077,0.00001443121,0.0007324786],"genre_scores_gemma":[0.9953923,0.0004472318,0.001181181,0.0001351498,0.00002702655,0.0003827522,0.001712573,0.00001025094,0.0007114666],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001479613,"threshold_uncertainty_score":0.005975664,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.008380037681753981,"score_gpt":0.2678257201452106,"score_spread":0.2594456824634566,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}